Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE: A) will report first-quarter fiscal 2026 results after market close on Feb. 25, 2026 and will host a listen-only conference call/webcast at 1:30 p.m. PST the same day.
A recording will be available on the company's investor relations site for 90 days. Agilent reported $6.95 billion revenue in fiscal 2025 and employs about 18,000 people worldwide.
Agilent (NYSE: A) launched the Agilent S540MD Slide Scanner System on January 23, 2026, a whole slide imaging scanner for high-volume digital pathology in key European markets. Engineered for speed and scalability, the system holds up to 540 slides, supports continuous loading, standard rack compatibility, automated scanning modes, and AI-assisted tissue detection. The scanner is an Agilent-branded version of the Hamamatsu NanoZoomer S540MD and will be available as IVD initially in Germany, France, Belgium, Spain, Austria, Luxembourg, Italy, the UK, and Switzerland, with further European expansion and milestones planned for 2026.
Agilent (NYSE: A) announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026, 9:00–9:40 a.m. PST. A live audio webcast and replay will be available via Agilent’s investor relations website.
Agilent reported $6.95 billion in revenue for fiscal year 2025 and employs approximately 18,000 people worldwide. The presentation likely will review recent performance and strategic priorities; investors can access the webcast and contact investor relations for more information.
Agilent (NYSE: A) released a 21 CFR Part 11 compliance software upgrade for the xCELLigence RTCA eSight system on December 1, 2025. The software adds a compliance license and enhanced security features—secure user authentication, electronic signatures, and complete audit trails—enabling deployment in GMP-regulated manufacturing and quality control as well as drug discovery labs.
The upgrade is positioned to support continuity from early research to production, improve audit readiness, and simplify regulatory submissions while maintaining workflow efficiency and data quality.
Agilent (NYSE: A) reported Q4 FY2025 revenue $1.86B, up 9.4% reported and up 7.2% on a core basis versus Q4 2024, with GAAP EPS of $1.53 (up 25% YoY) and non-GAAP EPS of $1.59 (up 9% YoY). Full FY2025 revenue was $6.95B, up 6.7% reported; FY2025 GAAP EPS was $4.57 and non-GAAP EPS was $5.59. Management provided FY2026 guidance of $7.3B–$7.4B revenue (up 5%–7% reported) and non-GAAP EPS $5.86–$6.00; Q1 FY2026 revenue guidance is $1.79B–$1.82B with non-GAAP EPS $1.35–$1.38.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share. The dividend is payable on Jan. 28, 2026 to shareholders of record at the close of business on Jan. 6, 2026. The company said timing and amounts of future dividends remain subject to the board of directors’ determination and approval.
Agilent reported $6.51 billion in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide. The release includes customary forward-looking statement language about risks and uncertainties related to the dividend program.
Agilent (NYSE: A) will participate in Citi’s 2025 Global Healthcare Conference on Dec. 4, 2025. Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will take part in a fireside chat from 9:00 to 9:45 a.m. EDT in Miami.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.51 billion revenue in fiscal year 2024 and employs approximately 18,000 people worldwide.
Agilent (NYSE: A) awarded an Agilent Research Catalyst (ARC) grant to the University of California, Davis on behalf of Professor Marie Heffern on November 12, 2025.
The award funds research using Agilent instrumentation (8900 ICP-QQQ, 6546 Q-TOF LC/MS, Infinity II LC) to study metal–peptide interactions in incretin-based therapeutics (GLP-1 receptor agonists). The project will apply LC-ICP-MS, native MS, and high-resolution peptide mapping to assess effects on drug stability, formulation, and bioactivity, aiming to build a predictive framework to inform formulation strategies and reduce degradation.
Agilent (NYSE: A) will release fourth-quarter fiscal 2025 results after market close on Monday, Nov. 24, 2025. The company will host a listen-only conference call webcast at 1:30 p.m. PST the same day, with a recording available on Agilent's investor website for 90 days.
Agilent reported $6.51 billion revenue in fiscal 2024 and employs approximately 18,000 people. Webcast access is via the Events section of Agilent's Investor Relations site; investor and media contacts are provided for follow-up.
Agilent (NYSE: A) named Adam S. Elinoff as chief financial officer, effective Nov. 17, 2025. Elinoff joins from Amgen after 19 years, most recently serving as vice president of finance and treasurer, and previously managing a $6 billion P&L across 67 markets as regional CFO. Agilent reported $6.51 billion revenue for fiscal 2024. Rodney Gonsalves will return to his role as corporate controller and principal accounting officer.
The appointment emphasizes Elinoff’s experience in finance, strategy, M&A, and global transformations as Agilent executes its Ignite Operating System.